Inhibitor Therapeutics, Inc.
INTI
$0.0514
-$0.0086-14.33%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.98M | 1.97M | 1.97M | 2.14M | 2.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.66M | 3.45M | 3.39M | 3.55M | 3.41M |
| Operating Income | -3.66M | -3.45M | -3.39M | -3.55M | -3.41M |
| Income Before Tax | -3.34M | -3.08M | -3.02M | -3.17M | -3.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.34 | -3.08 | -3.02 | -3.17 | -3.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.34M | -3.08M | -3.02M | -3.17M | -3.03M |
| EBIT | -3.66M | -3.45M | -3.39M | -3.55M | -3.41M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 689.05M | 688.75M | 688.44M | 688.08M | 687.80M |
| Average Diluted Shares Outstanding | 689.05M | 688.75M | 688.44M | 688.08M | 687.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
